Source: Eur Respir J, 51 (5) 1701610; 10.1183/13993003.01610-2017
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Takahiko Otsuki, Taku Nakashima, Hironobu Hamada, Yusuke Takayama, Shin Akita, Takeshi Masuda, Yasushi Horimasu, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, Yoshihiro Miyata, Masayuki Miyake, Nobuoki Kohno, Morihito Okada, Noboru Hattori. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma. Eur Respir J, 51 (5) 1701610; 10.1183/13993003.01610-2017

Member's Comments

No comment yet.

Related content which might interest you: Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma Source: Annual Congress 2008 - Inorganic dust exposure and the lung Year: 2008 Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 ADAM10 membrane-bound protease mediates malignant pleural mesothelioma invasiveness Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018 Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Comparison of telomerase activity in malignant and benign pleural effusions Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Multimodality therapy for malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Satisfractory therapeutic effects of EGFR-TK treatment of a malignant mesothelioma of the pleura: a case report Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Source: Eur Respir J 2010; 36: 1099-1105 Year: 2010 Management of malignant pleural mesothelioma Source: School Course 2014 - Medical Thoracoscopy Year: 2014 Management of malignant pleural mesothelioma Source: Hands-on Course 2012 - Medical Thoracoscopy Year: 2012 Management of malignant pleural mesothelioma Source: ERS Skills Course 2015 Year: 2015 Management of malignant pleural mesothelioma Source: Hands-on Course 2013 - Medical Thoracoscopy Year: 2013 Management of malignant pleural mesothelioma Source: ERS Course 2016 - Skills course on medical thoracoscopy Year: 2016